Skip to main content

Main menu

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums

User menu

  • My alerts

Search

  • Advanced search
The College of Family Physicians of Canada
  • Other Publications
    • http://www.cfpc.ca/Canadianfamilyphysician/
    • https://www.cfpc.ca/Login/
    • Careers and Locums
  • My alerts
The College of Family Physicians of Canada

Advanced Search

  • Home
  • Articles
    • Current
    • Published Ahead of Print
    • Archive
    • Supplemental Issues
    • Collections - French
    • Collections - English
  • Info for
    • Authors & Reviewers
    • Submit a Manuscript
    • Advertisers
    • Careers & Locums
    • Subscribers
    • Permissions
  • About CFP
    • About CFP
    • About the CFPC
    • Editorial Advisory Board
    • Terms of Use
    • Contact Us
  • Feedback
    • Feedback
    • Rapid Responses
    • Most Read
    • Most Cited
    • Email Alerts
  • Blogs
    • Latest Blogs
    • Blog Guidelines
    • Directives pour les blogues
  • Mainpro+ Credits
    • About Mainpro+
    • Member Login
    • Instructions
  • RSS feeds
  • Follow cfp Template on Twitter
  • LinkedIn
  • Instagram
Research ArticlePractice

ADHD stimulants and their effect on height in children

Ran D. Goldman
Canadian Family Physician February 2010; 56 (2) 145-146;
Ran D. Goldman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: rgoldman@cw.bc.ca
  • Article
  • eLetters
  • Info & Metrics
  • PDF
Loading

Abstract

QUESTION Many more children today are diagnosed and treated for attention deficit hyperactivity disorder. Parents frequently ask me if the stimulant medications their children receive might affect their height as adults. What should I tell them?

ANSWER Stimulant medications, including methylphenidate and amphetamine, are safe and effective in children and adolescents with attention deficit hyperactivity disorder. Research on the issue of growth suppression is lacking, mostly owing to insufficient follow-up on patients’ final heights. In general, the rate of height loss seems relatively small and is likely reversible with withdrawal of treatment. Clinical presentation and academic achievements should be the key to determining which drug to prescribe, the preparation, and the dose.

The prevalence of attention deficit hyperactivity disorder (ADHD) among school-aged children and adolescents is estimated to be 3% to 16%, depending on the classification system used, with boys 2 to 4 times more likely to be diagnosed with ADHD than girls.1 Beyond childhood, ADHD is increasingly being discussed as a serious psychiatric disorder in adulthood, with high heterogeneity and comorbidity with other psychiatric disorders.1 Typical psychiatric comorbidities in patients with ADHD include oppositional defiant disorder, conduct disorder, major depressive disorder, bipolar disorder, anxiety, substance abuse disorders, tic disorder, and Tourette syndrome.2

Children showing ADHD symptoms should be viewed as a group at high risk of suboptimal outcomes as young adults. Intervention programs for children with ADHD could be beneficial for preventing crime and drug abuse.3

Treatment of ADHD

Current research suggests that the combination of behavioural therapy (eg, behavioural parent training, school consultation, and direct contingency management) and pharmacotherapy might benefit most patients. Stimulant medications remain the medical treatment of choice for patients with ADHD and are associated with an exceptional response rate.2 Stimulant medications, including methylphenidate and amphetamine, are safe and effective in children and adolescents.4 These drugs come in numerous formulations, leading to some confusion and potential errors in prescribing and dispensing these drugs. Knowing and understanding the advantages and disadvantages of the different formulations can lead to individualized treatment.4

Although stimulants have a favourable risk-benefit profile, they do carry potential risks for children using them.5 Suppression of appetite and weight loss are commonly discussed adverse events. Sudden death was also reported in children using stimulants. A recent joint position statement by the Canadian Paediatric Society, the Canadian Cardiovascular Society, and the Canadian Academy of Child and Adolescent Psychiatry6 suggested that there should be a thorough history and physical examination with an emphasis on the identification of risk factors for sudden death before starting stimulant medications. However, no routine electrocardiographic screening or cardiac subspecialist consultation is needed.

Stimulants and growth

Do stimulants have long-term effects on growth and adult height? There are 3 main mechanisms that can affect height growth in children receiving stimulant medications. First, suppression of appetite is described among children,7 and reduction in caloric intake can negatively affect potential growth in children. A second proposed mechanism is associated with the dopaminergic effect of stimulants.8 Dopamine might suppress growth hormone secretion and directly affect height development in children. Finally, some studies suggest that stimulants might slow down the growth of cartilage tissue, affecting growth of bones.8

Understanding growth

While there are numerous published studies in the medical literature, there are still more questions than answers. The main challenge is conducting a study that will follow up on children using stimulants for many years, until their adult lives.

In a recent meta-analysis, Faraone et al8 made an effort to determine if stimulants affected height in children. Despite a range of studies, comparison was not possible owing to different definitions of ADHD and outcome measures in those studies. The authors ended up summarizing a qualitative review. In most of the studies, height velocity was negatively affected by stimulants early in the treatment period but approached normalized growth later on. The investigators concluded that treatment with stimulants in childhood modestly reduced expected height (and weight). They recognized the fact that these effects attenuated over time and that some data suggested that ultimate adult growth parameters were not affected.

Most studies have concluded that while some effect on growth is apparent, discontinuation of treatment results in a rebound of growth to compensate for stimulant-induced loss in height. This is the basis for recommending “summer breaks”—when children forego stimulant treatment when on summer holiday from school. A study in the early 1970s showed the beneficial effect on growth after one summer of terminating treatment with stimulant drugs9; a decade later a study found that after 1 summer no group difference in height was found, but 2 summers of discontinuing methylphenidate treatment had a positive effect on height.10

As to a potential dose-dependent growth effect, studies reported conflicting results and were influenced by small sample sizes, sex selection, and other biases. Determining the smallest dose of stimulant that affects ADHD symptom presentation is likely the best course of treatment for children.8

Conclusion

While follow-up by family physicians should include monitoring growth of children taking stimulants for ADHD, the rate of height loss seems relatively small and is likely reversible with withdrawal of treatment. Clinical presentation and academic achievements should be the key to determining the drug, the preparation, and the dose used.

PRETx

Child Health Update is produced by the Pediatric Research in Emergency Therapeutics (PRETx) program (www.pretx.org) at the BC Children’s Hospital in Vancouver, BC. Dr Goldman is Director of the PRETx program. The mission of the PRETx program is to promote child health through evidence-based research in therapeutics in pediatric emergency medicine.

Do you have questions about the effects of drugs, chemicals, radiation, or infections in children? We invite you to submit them to the PRETx program by fax at 604 875-2414; they will be addressed in future Child Health Updates. Published Child Health Updates are available on the Canadian Family Physician website (www.cfp.ca).

Footnotes

  • Competing interests

    None declared

  • Copyright© the College of Family Physicians of Canada

References

  1. ↵
    SchmidtSPetermannFDevelopmental psychopathology: attention deficit hyperactivity disorder (ADHD)BMC Psychiatry2009958
    OpenUrlPubMed
  2. ↵
    WigalSBEfficacy and safety limitations of attention-deficit hyperactivity disorder pharmacotherapy in children and adultsCNS Drugs200923Suppl 12131
    OpenUrlCrossRefPubMed
  3. ↵
    FletcherJWolfeBLong-term consequences of childhood ADHD on criminal activitiesJ Ment Health Policy Econ200912311938
    OpenUrlPubMed
  4. ↵
    ChavezBSopkoMAJrEhretMJPaulinoREGoldbergKRAngstadtKAn update on central nervous system stimulant formulations in children and adolescents with attention-deficit/hyperactivity disorderAnn Pharmacother2009436108495Epub 2009 May 26
    OpenUrlCrossRefPubMed
  5. ↵
    VitielloBUnderstanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular functionChild Adolesc Psychiatr Clin N Am200817245974xi
    OpenUrlCrossRefPubMed
  6. ↵
    WarrenAEHamiltonRMBélangerSAGrayCGowRMSanataniSCardiac risk assessment before the use of stimulant medications in children and youth: a joint position statement by the Canadian Paediatric Society, the Canadian Cardiovascular Society, and the Canadian Academy of Child and Adolescent PsychiatryCan J Cardiol2009251162530
    OpenUrlPubMed
  7. ↵
    EfronDJarmanFBarkerMSide effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trialPediatrics199710046626
    OpenUrlAbstract/FREE Full Text
  8. ↵
    FaraoneSVBiedermanJMorleyCPSpencerTJEffect of stimulants on height and weight: a review of the literatureJ Am Acad Child Adolesc Psychiatry20084799941009
    OpenUrlCrossRefPubMed
  9. ↵
    SaferDJAllenRPBarrEGrowth rebound after termination of stimulant drugsJ Pediatr19758611136
    OpenUrlCrossRefPubMed
  10. ↵
    KleinRGLandaBMattesJAKleinDFMethylphenidate and growth in hyperactive children. A controlled withdrawal studyArch Gen Psychiatry19884512112730
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

Canadian Family Physician: 56 (2)
Canadian Family Physician
Vol. 56, Issue 2
1 Feb 2010
  • Table of Contents
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on The College of Family Physicians of Canada.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
ADHD stimulants and their effect on height in children
(Your Name) has sent you a message from The College of Family Physicians of Canada
(Your Name) thought you would like to see the The College of Family Physicians of Canada web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
ADHD stimulants and their effect on height in children
Ran D. Goldman
Canadian Family Physician Feb 2010, 56 (2) 145-146;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Respond to this article
Share
ADHD stimulants and their effect on height in children
Ran D. Goldman
Canadian Family Physician Feb 2010, 56 (2) 145-146;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Treatment of ADHD
    • Stimulants and growth
    • Understanding growth
    • Conclusion
    • Footnotes
    • References
  • eLetters
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Practice

  • Managing type 2 diabetes in primary care during COVID-19
  • Effectiveness of dermoscopy in skin cancer diagnosis
  • Spontaneous pneumothorax in children
Show more Practice

Child Health Update

  • Accidental cannabis ingestion in young children
  • All-terrain vehicle injuries in children and adolescents
  • Screen time and sleep in children
Show more Child Health Update

Similar Articles

Navigate

  • Home
  • Current Issue
  • Archive
  • Collections - English
  • Collections - Française

For Authors

  • Authors and Reviewers
  • Submit a Manuscript
  • Permissions
  • Terms of Use

General Information

  • About CFP
  • About the CFPC
  • Advertisers
  • Careers & Locums
  • Editorial Advisory Board
  • Subscribers

Journal Services

  • Email Alerts
  • Twitter
  • LinkedIn
  • Instagram
  • RSS Feeds

Copyright © 2025 by The College of Family Physicians of Canada

Powered by HighWire